Alcon

ALC

Market cap $33.7B

ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.

DELL, Brinker International, Tapestry and Alcon pair strong interest coverage with solid growth prospects amid elevated borrowing costs.

RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustable intraocular lenses.

The mean of analysts' price targets for Alcon (ALC) points to a 27.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Alcon (ALC) or Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Alcon's new platforms, lenses and dry eye momentum support growth, but macro pressures, tariffs and fierce competition weigh on its outlook.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2026) - Mexican Gold Mining Corp. (TSXV: MEX) ("Mexican Gold" or the "Company") and Alcon Silver Corp. ("Alcon") announce that, in connection with the previously announced arrangement agreement dated April 8, 2026 between the Company and Alcon (the "Arrangement Agreement"), the Company intends to complete a non-brokered private placement of up to 11,250,000 subscription receipts of the Company (the "Subscription Receipts") at a price of $0.20 per Subscription Receipt, for aggregate gross proceeds of up to $2,250,000 (the "Offering"). The Offering constitutes a concurrent financing to the Arrangement (as defined below) and is subject to acceptance of the TSX Venture Exchange (the "TSXV").

Arm Holdings' management reiterated confidence in sustaining approximately 20% royalty growth longer term, reinforcing the market's confidence in Arm's structural growth profile. Adyen was a detractor from performance during the quarter following fourth quarter results and a more cautious 2026 outlook. We initiated a new position in American Express and exited our positions in Gartner and UnitedHealth.